Hassan Mohamed
Division of Cardiology, Aswan Heart Centre, Aswan, Egypt.
Glob Cardiol Sci Pract. 2017 Mar 31;2017(1):e201706. doi: 10.21542/gcsp.2017.6.
Angiopoietin-like proteins (ANGPTLs) have emerged as an important regulator of lipid and glucose metabolism as well as insulin sensitivity. ANGPTL3 plays a key role in regulating circulating triglycerides (TG) and cholesterol levels through reversible inhibition of lipoprotein lipase (LPL) and endothelial lipase enzymes activity. Loss of function mutation of ANGPTL3 gene has been identified in many subjects with familial combined hypolipidemia. ANGPTL4 produces irreversible inhibition of LPL activity, while ANGPTL8 enhances the activity of ANGPTL3, which highlight the interplay between the different ANGPTLs in a coordinated manner to regulate lipid metabolism during different nutritional states. This new class of lipid modulators may serve as potential novel therapeutic target for reducing plasma lipoprotein and treatment of metabolic syndrome.
血管生成素样蛋白(ANGPTLs)已成为脂质和葡萄糖代谢以及胰岛素敏感性的重要调节因子。血管生成素样蛋白3(ANGPTL3)通过可逆性抑制脂蛋白脂肪酶(LPL)和内皮脂肪酶的活性,在调节循环甘油三酯(TG)和胆固醇水平方面发挥关键作用。在许多家族性混合性血脂异常患者中已发现血管生成素样蛋白3基因的功能丧失突变。血管生成素样蛋白4(ANGPTL4)对脂蛋白脂肪酶活性产生不可逆抑制,而血管生成素样蛋白8(ANGPTL8)增强血管生成素样蛋白3的活性,这突出了不同血管生成素样蛋白之间以协调方式相互作用,以在不同营养状态下调节脂质代谢。这类新的脂质调节剂可能成为降低血浆脂蛋白和治疗代谢综合征的潜在新型治疗靶点。